{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:14:51Z","timestamp":1760919291810,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.htct.2025.103977","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:08:08Z","timestamp":1757171288000},"page":"103977","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Daratumumab-EPOCH for transformed anaplastic multiple myeloma"],"prefix":"10.1016","volume":"47","author":[{"given":"Espen","family":"Stormorken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4477-3526","authenticated-orcid":false,"given":"Anders Erik Astrup","family":"Dahm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.htct.2025.103977_bib0001","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1097\/CM9.0000000000000902","article-title":"Clinical and histopathological analyses of anaplastic myeloma","volume":"133","author":"Huang","year":"2020","journal-title":"Chin Med J (Engl)"},{"issue":"3\u20134","key":"10.1016\/j.htct.2025.103977_bib0002","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3109\/07357909009012059","article-title":"Aggressive phase multiple myeloma: a terminal anaplastic transformation resembling high-grade lymphoma","volume":"8","author":"Allen","year":"1990","journal-title":"Cancer Invest"},{"issue":"3","key":"10.1016\/j.htct.2025.103977_bib0003","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2020)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Annal Oncology"},{"issue":"1","key":"10.1016\/j.htct.2025.103977_bib0004","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3960\/jslrt.17035","article-title":"Anaplastic multiple myeloma: possible limitations of conventional chemotherapy for long-term remission","volume":"58","author":"Ichikawa","year":"2018","journal-title":"J Clin Exp Hematop"},{"issue":"8","key":"10.1016\/j.htct.2025.103977_bib0005","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1200\/JCO.1993.11.8.1573","article-title":"EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma","volume":"11","author":"Wilson","year":"1993","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.htct.2025.103977_bib0006","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/1097-0142(197307)32:1<69::AID-CNCR2820320109>3.0.CO;2-0","article-title":"Pomp combination chemotherapy of adult acute leukemia","volume":"32","author":"Rodriguez","year":"1973","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.htct.2025.103977_bib0007","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.htct.2025.103977_bib0008","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1007\/s00277-020-04244-7","article-title":"Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy","volume":"100","author":"Tang","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.htct.2025.103977_bib0009","article-title":"Anaplastic multiple myeloma with MYC rearrangement","volume":"17","author":"Ichikawa","year":"2022","journal-title":"Leuk Res Rep"},{"issue":"1","key":"10.1016\/j.htct.2025.103977_bib0010","doi-asserted-by":"crossref","first-page":"132","DOI":"10.29271\/jcpsp.2022.01.132","article-title":"Anaplastic multiple myeloma with multiple genetic anomalies","volume":"32","author":"Demircioglu","year":"2022","journal-title":"J Coll Physic Surg Pak"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137925002457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137925002457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T07:22:41Z","timestamp":1760858561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137925002457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2531137925002457"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2025.103977","relation":{},"ISSN":["2531-1379"],"issn-type":[{"type":"print","value":"2531-1379"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daratumumab-EPOCH for transformed anaplastic multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2025.103977","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"103977"}}